A trial of gataparsen and docetaxel for non small cell lung cancer
Cancer type:
Status:
Phase:
This trial compared gataparsen and docetaxel together with docetaxel alone, for non small cell lung cancer that has spread.
More about this trial
- see if the combination of docetaxel and gataparsen works better than docetaxel alone for advanced non small cell lung cancer
- learn more about the side effects
Summary of results
- 120 people in the docetaxel and gataparsen group
- 60 people in the docetaxel group
- 3.3 months for those who had docetaxel
- 2.8 months for those who had docetaxel and gataparsen
- 8.8 months for those who had docetaxel
- 7.9 months for those who had docetaxel and gataparsen
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Denis Talbot
Supported by
Eli Lilly and Company Limited
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040